Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348365 | 0.85 | CRBN (0.42) | DDB1CRBNPDCD1CD274BRD4 | |
| SCHEMBL29348347 | 0.85 | CRBN (0.41) | DDB1CRBNPDCD1CD274 | |
| SCHEMBL29348364 | 0.84 | DDB1 (0.50) | DDB1CRBNPDCD1CD274L3MBTL1 | |
| SCHEMBL29348357 | 0.81 | DDB1 (0.43) | DDB1CRBNPDCD1CD274L3MBTL1 | |
| SCHEMBL29348374 | 0.80 | DDB1 (0.46) | DDB1CRBN | |
| SCHEMBL29348363 | 0.76 | DDB1 (0.52) | DDB1CRBNBRD4CREBBP | |
| SCHEMBL29348340 | 0.75 | DDB1 (0.46) | DDB1CRBNBRD4 | |
| SCHEMBL29348370 | 0.75 | DDB1 (0.46) | DDB1CRBNBRD4CREBBP | |
| SCHEMBL31068241 | 0.75 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL31068205 | 0.75 | DRD2 (0.43) | DDB1CRBNCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |